CSPC Pharmaceutical (HKG:1093) said the Anbenitamab Injection has met the primary endpoint in a phase III study and demonstrated improved total pathological complete response, according to a Tuesday Hong Kong bourse filing.
Shares of the pharmaceutical firm were up over 6% in Wednesday afternoon trading.
The Anbenitamab Injection is co-developed by CSPC Pharmaceutical's unit Shanghai JMT-BIO Technology and Alphamab Oncology's (HKG:9966) subsidiary Jiangsu Alphamab Oncology.
The trial is studying the drug in combination with Docetaxel for Injection for the treatment of HER2-positive early or locally advanced breast cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments